Quote | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
Last: | $ |
---|---|
Change Percent: | 2.29% |
Open: | $2.15 |
Close: | $2.23 |
High: | $2.29 |
Low: | $2.15 |
Volume: | 51,911 |
Last Trade Date Time: | 02/12/2020 04:43:17 pm |
News | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Message Board Posts | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
Subject | By | Source | When |
---|---|---|---|
The company more than likely will announce a | Sierra20 | investorshub | 04/20/2023 4:52:51 AM |
NEWS -- Plus Therapeutics Completes Enrollment of the | Paulness | investorshub | 04/19/2023 11:51:05 AM |
NEWS -- Plus Therapeutics to Participate in Panel | Paulness | investorshub | 04/19/2023 12:00:25 AM |
NEWS -- Plus Therapeutics Completes Phase 1/Part A | Paulness | investorshub | 04/18/2023 11:33:10 AM |
May announce reverse split on 4/20? | Sierra20 | investorshub | 04/12/2023 1:57:16 PM |
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...